Pharma Focus Asia

Pharma Focus Asia Pharma Focus Asia - Magazine for Pharma Industry Leaders
https://www.linkedin.com/company/pharmafocusasia/ Ltd.. Pharma Focus Asia offers . . .

Pharma Focus Asia is a half yearly publication from Ochre Media Pvt. It is the leading pharma title in print and digital versions serving the information needs of key executives from the worldโ€™s leading pharmaceutical companies. Pharma Focus Asia covers important issues and trends shaping the future of the pharma industry across Asia and rest of the world. Dedicated, reliable and accurate coverage

of the industryโ€™s progress and
Incisive analysis to help its readers make informed decisions to stay ahead of the competition. The magazine provides cutting-edge and futuristic content on the pharma industry. The issues are broadly categorized into various sections:

Strategy
Research and Development
Manufacturing
Clinical Trials
Information Technology


The one-stop pharma destination www.pharmafocusasia.com features complete content from the Pharma Focus Asia magazine. Also find the latest pharma news, press releases, pharma industry reports, interviews, trends and pharma events updated on a daily basis. The magazine is supplemented by the monthly e-Newsletter: Verticaltalk Pharma. The readership

The magazineโ€™s readership includes the top C-level executives, senior industry executives, and key decision makers from the pharma industry in charge of spending. With a special focus on Asia, Pharma Focus Asia reaches out to the key industry leaders across Asia, Europe and the Americas.

๐๐ก๐š๐ซ๐ฆ๐š ๐…๐จ๐œ๐ฎ๐ฌ ๐€๐ฌ๐ข๐š ๐ˆ๐ฌ๐ฌ๐ฎ๐ž ๐Ÿ”๐Ÿ’ | ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” ๐ˆ๐ฌ ๐๐จ๐ฐ ๐‹๐ข๐ฏ๐ž! ๐Ÿ“–The latest issue of Pharma Focus Asia is here, bringing together expert ...
04/09/2026

๐๐ก๐š๐ซ๐ฆ๐š ๐…๐จ๐œ๐ฎ๐ฌ ๐€๐ฌ๐ข๐š ๐ˆ๐ฌ๐ฌ๐ฎ๐ž ๐Ÿ”๐Ÿ’ | ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” ๐ˆ๐ฌ ๐๐จ๐ฐ ๐‹๐ข๐ฏ๐ž! ๐Ÿ“–

The latest issue of Pharma Focus Asia is here, bringing together expert insights and emerging developments shaping the future of the pharmaceutical industry.

๐ˆ๐ง ๐“๐ก๐ข๐ฌ ๐ˆ๐ฌ๐ฌ๐ฎ๐ž:
โ€ข Engaging patients earlier in pharmaceutical development
โ€ข Advances across Research & Development
โ€ข Innovations in pharmaceutical manufacturing
โ€ข The growing impact of Information Technology
โ€ข Expert perspectives on key industry trends
โ€ข Latest developments across BioPharma

๐–๐ก๐ฒ ๐ˆ๐ญ ๐Œ๐š๐ญ๐ญ๐ž๐ซ๐ฌ:
As pharma continues to evolve through scientific innovation, technology, and changing patient needs, staying informed has never been more important.

A big thank you to all our contributors, experts, partners, and industry professionals who made this issue possible.

๐Ÿ“– ๐„๐ฑ๐ฉ๐ฅ๐จ๐ซ๐ž ๐ˆ๐ฌ๐ฌ๐ฎ๐ž ๐Ÿ”๐Ÿ’: https://www.pharmafocusasia.com/magazine

Discover the insights. Explore the innovations. Stay ahead of whatโ€™s next in pharma.

๐„๐ฆ๐ž๐ซ๐ ๐ข๐ง๐  ๐“๐ž๐œ๐ก๐ง๐จ๐ฅ๐จ๐ ๐ข๐ž๐ฌ ๐ข๐ง ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ ๐’๐œ๐ข๐ž๐ง๐œ๐ž๐ฌ: ๐…๐ซ๐จ๐ฆ ๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ ๐ญ๐จ ๐ƒ๐ž๐ฅ๐ข๐ฏ๐ž๐ซ๐ฒ, ๐ญ๐ก๐ž ๐“๐ซ๐š๐ง๐ฌ๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐‡๐š๐ฌ ๐€๐ฅ๐ซ๐ž๐š๐๐ฒ ๐๐ž๐ ๐ฎ๐งArtifi...
04/09/2026

๐„๐ฆ๐ž๐ซ๐ ๐ข๐ง๐  ๐“๐ž๐œ๐ก๐ง๐จ๐ฅ๐จ๐ ๐ข๐ž๐ฌ ๐ข๐ง ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ ๐’๐œ๐ข๐ž๐ง๐œ๐ž๐ฌ: ๐…๐ซ๐จ๐ฆ ๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ ๐ญ๐จ ๐ƒ๐ž๐ฅ๐ข๐ฏ๐ž๐ซ๐ฒ, ๐ญ๐ก๐ž ๐“๐ซ๐š๐ง๐ฌ๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐‡๐š๐ฌ ๐€๐ฅ๐ซ๐ž๐š๐๐ฒ ๐๐ž๐ ๐ฎ๐ง

Artificial intelligence, digital twins, and agentic AI are moving beyond experimentation and beginning to reshape how pharmaceutical companies discover, develop, manufacture, and monitor medicines.

In Pharma Focus Asia, Abhishek Rungta, Founder and CEO, INT. (Indus Net Technologies Ltd.), explores how emerging technologies are transforming the pharmaceutical value chainโ€”and what this shift could mean for pharmaceutical companies across Asia.

๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:
โ€ข How AI is accelerating drug discovery and creating opportunities to reduce development timelines and costs
โ€ข The growing role of digital twins across drug discovery, manufacturing, supply chains, and personalised medicine
โ€ข How agentic AI is transforming clinical operations and pharmacovigilance
โ€ข The potential of AI-driven systems to automate complex, multi-step pharmaceutical workflows
โ€ข Why integrated data architecture is becoming critical for enterprise-grade pharmaceutical AI

๐–๐ก๐ฒ ๐ˆ๐ญ ๐Œ๐š๐ญ๐ญ๐ž๐ซ๐ฌ:
The future of pharmaceutical innovation will not be defined by individual technologies alone, but by how effectively they work together across the entire drug lifecycle.

AI can accelerate discovery. Digital twins can improve prediction and operational resilience. Agentic systems can automate complex workflows. But their full potential emerges when these capabilities are connected through reliable data, integrated platforms, and responsible governance.

๐Ÿ”— ๐‘๐ž๐š๐ ๐ญ๐ก๐ž ๐Ÿ๐ฎ๐ฅ๐ฅ ๐š๐ซ๐ญ๐ข๐œ๐ฅ๐ž:
https://www.pharmafocusasia.com/articles/emerging-technologies-in-pharmaceutical-sciences

๐€๐๐ฏ๐š๐ง๐œ๐ข๐ง๐  ๐๐ก๐š๐ซ๐ฆ๐š ๐ˆ๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐ง & ๐ƒ๐ซ๐ฎ๐  ๐ƒ๐ž๐ฏ๐ž๐ฅ๐จ๐ฉ๐ฆ๐ž๐ง๐ญ ๐€๐œ๐ซ๐จ๐ฌ๐ฌ ๐€๐๐€๐‚!The Pharma Focus Asia team met with Koji Tanimoto, Senior Dir...
04/09/2026

๐€๐๐ฏ๐š๐ง๐œ๐ข๐ง๐  ๐๐ก๐š๐ซ๐ฆ๐š ๐ˆ๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐ง & ๐ƒ๐ซ๐ฎ๐  ๐ƒ๐ž๐ฏ๐ž๐ฅ๐จ๐ฉ๐ฆ๐ž๐ง๐ญ ๐€๐œ๐ซ๐จ๐ฌ๐ฌ ๐€๐๐€๐‚!

The Pharma Focus Asia team met with Koji Tanimoto, Senior Director, Biotech Account Management, APAC at Thermo Fisher Scientific, at ISPE Singapore to explore the evolving pharmaceutical and biotech landscape across Asia-Pacific.

๐“๐ก๐ž ๐ข๐ง๐ฌ๐ข๐ ๐ก๐ญ๐Ÿ๐ฎ๐ฅ ๐œ๐จ๐ง๐ฏ๐ž๐ซ๐ฌ๐š๐ญ๐ข๐จ๐ง ๐œ๐จ๐ฏ๐ž๐ซ๐ฌ:
Key trends driving pharmaceutical and biotech innovation across APAC
The growing complexity of advanced modalities, including cell and gene therapies
How biotechs can translate scientific innovation into executable development programmes
The value of integrated CDMO and CRO capabilities in reducing handoffs and complexity
Key factors to consider when selecting development and manufacturing partners
How strong CMC capabilities can support future licensing opportunities
Balancing speed, quality, regulatory requirements and seamless ex*****on

From the regionโ€™s growing innovation pipeline to increasingly complex development programmes, Tanimoto shares practical perspectives on how biotechs can reduce complexity, accelerate development and build stronger partnerships throughout the drug development journey.

๐–๐š๐ญ๐œ๐ก ๐ญ๐ก๐ž ๐Ÿ๐ฎ๐ฅ๐ฅ ๐ข๐ง๐ญ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ | ๐’๐ก๐š๐ซ๐ž ๐ฐ๐ข๐ญ๐ก ๐ฒ๐จ๐ฎ๐ซ ๐ญ๐ž๐š๐ฆ!
https://www.pharmafocusasia.com/interviews/koji-tanimoto-thermo-fisher-scientific

๐–๐žโ€™๐ซ๐ž ๐›๐ซ๐ข๐ง๐ ๐ข๐ง๐  ๐ฒ๐จ๐ฎ ๐š๐ง ๐ž๐ฑ๐œ๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ž ๐ข๐ง๐ญ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ ๐จ๐ง ๐ƒ๐ข๐ ๐ข๐ญ๐š๐ฅ ๐“๐ซ๐š๐ง๐ฌ๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐ข๐ง ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ ๐Œ๐š๐ง๐ฎ๐Ÿ๐š๐œ๐ญ๐ฎ๐ซ๐ข๐ง๐ !The Pharma Focus Asi...
03/09/2026

๐–๐žโ€™๐ซ๐ž ๐›๐ซ๐ข๐ง๐ ๐ข๐ง๐  ๐ฒ๐จ๐ฎ ๐š๐ง ๐ž๐ฑ๐œ๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ž ๐ข๐ง๐ญ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ ๐จ๐ง ๐ƒ๐ข๐ ๐ข๐ญ๐š๐ฅ ๐“๐ซ๐š๐ง๐ฌ๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐ข๐ง ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ ๐Œ๐š๐ง๐ฎ๐Ÿ๐š๐œ๐ญ๐ฎ๐ซ๐ข๐ง๐ !

The Pharma Focus Asia team spoke with David Holt about how pharmaceutical manufacturers are embracing new technologies to modernize their operations and accelerate digital transformation.

๐–๐žโ€™๐ฅ๐ฅ ๐›๐ž ๐›๐ซ๐ข๐ง๐ ๐ข๐ง๐  ๐ฒ๐จ๐ฎ:
Key digital transformation trends in pharma manufacturing
Insights on composable digitalization and MES
The growing role of AI in manufacturing
Challenges around validation and regulatory compliance
Practical approaches to accelerating digital transformation

From moving beyond point solutions to adopting composable platforms, modern MES and governed AI, this conversation explores how pharma companies can build more agile, connected and efficient manufacturing environments.

๐–๐š๐ญ๐œ๐ก ๐ญ๐ก๐ž ๐Ÿ๐ฎ๐ฅ๐ฅ ๐ข๐ง๐ญ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ | ๐’๐ก๐š๐ซ๐ž ๐ฐ๐ข๐ญ๐ก ๐ฒ๐จ๐ฎ๐ซ ๐ญ๐ž๐š๐ฆ!
https://www.pharmafocusasia.com/interviews/david-holt-factorytalk

๐๐ก๐š๐ซ๐ฆ๐š ๐…๐จ๐œ๐ฎ๐ฌ ๐€๐ฌ๐ข๐š โ€” ๐€๐ฎ๐ ๐ฎ๐ฌ๐ญ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” ๐„-๐๐ž๐ฐ๐ฌ๐ฅ๐ž๐ญ๐ญ๐ž๐ซThe August 2026 edition of the Pharma Focus Asia E-Newsletter brings togethe...
21/08/2026

๐๐ก๐š๐ซ๐ฆ๐š ๐…๐จ๐œ๐ฎ๐ฌ ๐€๐ฌ๐ข๐š โ€” ๐€๐ฎ๐ ๐ฎ๐ฌ๐ญ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” ๐„-๐๐ž๐ฐ๐ฌ๐ฅ๐ž๐ญ๐ญ๐ž๐ซ

The August 2026 edition of the Pharma Focus Asia E-Newsletter brings together expert perspectives, pharmaceutical industry developments, emerging technologies, research insights, corporate updates, and upcoming events shaping the healthcare and life sciences landscape across Asia and beyond.

From next-generation oral peptides and generic regulatory pathways to AI in predictive toxicology, the latest edition offers a diverse view of scientific, technological, regulatory, and commercial developments influencing the pharmaceutical industry.

๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:
โ€ข Expert insights on navigating mucosal toxicity in next-generation oral peptides
โ€ข Regulatory perspectives on generic approvals across Latin American markets
โ€ข Exploring AI hallucinations and their implications for predictive toxicology
โ€ข Latest pharmaceutical news, product approvals, and corporate developments
โ€ข Emerging technology trends and breakthrough pharmaceutical innovations
โ€ข Industry press releases and major investment projects
โ€ข Research insights across drug discovery, genomics, AI, and biotechnology
โ€ข Upcoming pharmaceutical, healthcare, and life sciences events
โ€ข Latest whitepapers and industry-focused resources

๐–๐ก๐ฒ ๐ˆ๐ญ ๐Œ๐š๐ญ๐ญ๐ž๐ซ๐ฌ:
The pharmaceutical landscape is evolving rapidly across drug delivery, regulatory science, artificial intelligence, research, and commercial innovation. The August 2026 Pharma Focus Asia E-Newsletter brings these developments together, helping pharma and life sciences professionals stay informed about the ideas, technologies, investments, and industry shifts shaping the future of healthcare.

๐Ÿ“– ๐„๐ฑ๐ฉ๐ฅ๐จ๐ซ๐ž ๐ญ๐ก๐ž ๐ฅ๐š๐ญ๐ž๐ฌ๐ญ ๐ž๐๐ข๐ญ๐ข๐จ๐ง:
https://industry.pharmafocusasia.com/e-newsletters/1787217138-Aug-26.html

20/08/2026

๐–๐žโ€™๐ซ๐ž ๐š๐ญ ๐ˆ๐’๐๐„ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” ๐’๐ข๐ง๐ ๐š๐ฉ๐จ๐ซ๐ž!

The ๐—ฃ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ ๐—™๐—ผ๐—ฐ๐˜‚๐˜€ ๐—”๐˜€๐—ถ๐—ฎ team is on the ground at the ISPE Singapore Affiliate Event, meeting industry leaders and experts.

Weโ€™ll be bringing you:
โœ”๏ธ Great interviews
โœ”๏ธ Latest industry updates
โœ”๏ธ New technologies
โœ”๏ธ Expert perspectives

Canโ€™t make it to Singapore? ๐—ฆ๐˜๐—ฎ๐˜† ๐—ฐ๐—ผ๐—ป๐—ป๐—ฒ๐—ฐ๐˜๐—ฒ๐—ฑ ๐˜„๐—ถ๐˜๐—ต ๐˜‚๐˜€.

Follow this space for exciting updates and exclusive conversations from the event!

๐๐š๐ฏ๐ข๐ ๐š๐ญ๐ข๐ง๐  ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ ๐…๐ซ๐š๐ฆ๐ž๐ฐ๐จ๐ซ๐ค๐ฌ: ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐€๐ฉ๐ฉ๐ซ๐จ๐ฏ๐š๐ฅ๐ฌ ๐ข๐ง ๐‹๐š๐ญ๐ข๐ง ๐€๐ฆ๐ž๐ซ๐ข๐œ๐šโ€™๐ฌ ๐“๐ฐ๐จ ๐†๐ข๐š๐ง๐ญ๐ฌ โ€” ๐๐ซ๐š๐ณ๐ข๐ฅ & ๐Œ๐ž๐ฑ๐ข๐œ๐จAs Latin Americaโ€™s ph...
20/08/2026

๐๐š๐ฏ๐ข๐ ๐š๐ญ๐ข๐ง๐  ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ ๐…๐ซ๐š๐ฆ๐ž๐ฐ๐จ๐ซ๐ค๐ฌ: ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐€๐ฉ๐ฉ๐ซ๐จ๐ฏ๐š๐ฅ๐ฌ ๐ข๐ง ๐‹๐š๐ญ๐ข๐ง ๐€๐ฆ๐ž๐ซ๐ข๐œ๐šโ€™๐ฌ ๐“๐ฐ๐จ ๐†๐ข๐š๐ง๐ญ๐ฌ โ€” ๐๐ซ๐š๐ณ๐ข๐ฅ & ๐Œ๐ž๐ฑ๐ข๐œ๐จ

As Latin Americaโ€™s pharmaceutical market continues to expand, Brazil and Mexico are emerging as key destinations for generic drug manufacturers. Understanding the differences in regulatory pathways, GMP requirements, dossier formats and approval timelines is essential for companies planning market entry.

In this contributed article for Pharma Focus Asia, Bhavya Sridevi Sundaraneedi, Masterโ€™s student of Regulatory Affairs, NIPER-Raebareli, and Dr. Rahul Shukla, Assistant Professor, Department of Pharmaceutics, NIPER-Raebareli, examine the regulatory frameworks governing generic drug approvals in Brazil and Mexico.

๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:
โ€ข The regulatory roles of ANVISA in Brazil and COFEPRIS in Mexico
โ€ข Key requirements for generic drug registration in both markets
โ€ข Differences in CTD and electronic dossier submission approaches
โ€ข GMP certification and inspection requirements for manufacturers
โ€ข Registration review timelines and associated fees in Brazil and Mexico
โ€ข The role of bioequivalence and biowaiver requirements in generic approvals

๐–๐ก๐ฒ ๐ˆ๐ญ ๐Œ๐š๐ญ๐ญ๐ž๐ซ๐ฌ:
Brazil and Mexico represent two of Latin Americaโ€™s most important pharmaceutical markets, but their regulatory pathways are not identical. Understanding country-specific requirements can help pharmaceutical companies plan submissions more effectively, anticipate GMP and documentation requirements, and navigate market-entry strategies with greater confidence.

๐Ÿ”— ๐‘๐ž๐š๐ ๐ญ๐ก๐ž ๐Ÿ๐ฎ๐ฅ๐ฅ ๐š๐ซ๐ญ๐ข๐œ๐ฅ๐ž:
https://www.pharmafocusasia.com/articles/navigating-regulatory-frameworks

๐Œ๐จ๐ฏ๐ข๐ง๐  ๐Ÿ๐ซ๐จ๐ฆ ๐‚๐จ๐๐ž ๐ญ๐จ ๐‚๐จ๐ง๐ฌ๐ž๐ช๐ฎ๐ž๐ง๐œ๐ž: ๐‚๐จ๐ง๐Ÿ๐ซ๐จ๐ง๐ญ๐ข๐ง๐  ๐€๐ˆ ๐‡๐š๐ฅ๐ฅ๐ฎ๐œ๐ข๐ง๐š๐ญ๐ข๐จ๐ง๐ฌ ๐ข๐ง ๐๐ซ๐ž๐๐ข๐œ๐ญ๐ข๐ฏ๐ž ๐“๐จ๐ฑ๐ข๐œ๐จ๐ฅ๐จ๐ ๐ฒAs pharmaceutical R&D increasingl...
20/08/2026

๐Œ๐จ๐ฏ๐ข๐ง๐  ๐Ÿ๐ซ๐จ๐ฆ ๐‚๐จ๐๐ž ๐ญ๐จ ๐‚๐จ๐ง๐ฌ๐ž๐ช๐ฎ๐ž๐ง๐œ๐ž: ๐‚๐จ๐ง๐Ÿ๐ซ๐จ๐ง๐ญ๐ข๐ง๐  ๐€๐ˆ ๐‡๐š๐ฅ๐ฅ๐ฎ๐œ๐ข๐ง๐š๐ญ๐ข๐จ๐ง๐ฌ ๐ข๐ง ๐๐ซ๐ž๐๐ข๐œ๐ญ๐ข๐ฏ๐ž ๐“๐จ๐ฑ๐ข๐œ๐จ๐ฅ๐จ๐ ๐ฒ

As pharmaceutical R&D increasingly moves toward AI-driven drug discovery and in silico safety prediction, generative AI is creating new opportunities to accelerate molecular design and identify potential toxicities before clinical development. But how reliable are these predictions when models encounter complex, human-specific biological responses?

In this contributed article for Pharma Focus Asia, Dr. Sanjesh Kumar, Assistant Professor, Chandigarh University, and Dr. Disha Marwaha, Assistant Professor, Chandigarh University, explore the growing challenge of AI hallucinations in predictive toxicology and the need to bridge computational predictions with human-relevant biological validation.

๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:
โ€ข Why AI-generated safety profiles can fail when models move beyond familiar datasets
โ€ข The challenge of predicting rare, human-specific idiosyncratic adverse drug reactions
โ€ข How data gaps and biological complexity can create false confidence in computational toxicity predictions
โ€ข The limitations of relying solely on in silico models for drug safety assessment
โ€ข How organ-on-a-chip technologies and patient-derived organoids can strengthen validation
โ€ข The role of real-time biological feedback in improving AI model predictions
โ€ข Why human oversight remains essential for responsible AI-driven drug development

๐–๐ก๐ฒ ๐ˆ๐ญ ๐Œ๐š๐ญ๐ญ๐ž๐ซ๐ฌ:
AI can dramatically accelerate drug discovery, but computational speed cannot replace biological evidence. Rare, patient-specific toxicities and complex immune-mediated responses remain difficult for current models to predict reliably.

A hybrid approach combining AI with human-relevant experimental systems, real-time biological feedback and expert oversight could help reduce false confidence, strengthen regulatory readiness and improve the safety of future medicines.

๐Ÿ”— ๐‘๐ž๐š๐ ๐ญ๐ก๐ž ๐Ÿ๐ฎ๐ฅ๐ฅ ๐š๐ซ๐ญ๐ข๐œ๐ฅ๐ž:
https://www.pharmafocusasia.com/articles/moving-from-code-to-consequence

๐๐ž๐ฎ๐ซ๐š๐ฅ ๐๐ž๐ญ๐ฐ๐จ๐ซ-๐ƒ๐ซ๐ข๐ฏ๐ž๐ง ๐‹๐ž๐š๐ ๐Ž๐ฉ๐ญ๐ข๐ฆ๐ข๐ณ๐š๐ญ๐ข๐จ๐ง ๐ฐ๐ข๐ญ๐ก ๐„๐ฆ๐›๐ž๐๐๐ž๐ ๐€๐ƒ๐Œ๐„๐“ ๐‚๐จ๐ฆ๐ฉ๐ฅ๐ข๐š๐ง๐œ๐žIn small-molecule drug development, the biggest cha...
19/08/2026

๐๐ž๐ฎ๐ซ๐š๐ฅ ๐๐ž๐ญ๐ฐ๐จ๐ซ-๐ƒ๐ซ๐ข๐ฏ๐ž๐ง ๐‹๐ž๐š๐ ๐Ž๐ฉ๐ญ๐ข๐ฆ๐ข๐ณ๐š๐ญ๐ข๐จ๐ง ๐ฐ๐ข๐ญ๐ก ๐„๐ฆ๐›๐ž๐๐๐ž๐ ๐€๐ƒ๐Œ๐„๐“ ๐‚๐จ๐ฆ๐ฉ๐ฅ๐ข๐š๐ง๐œ๐ž

In small-molecule drug development, the biggest challenge is often not achieving potency โ€” but identifying toxicity and pharmacokinetic liabilities before they become costly late-stage failures.

Conventional lead optimization often evaluates ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) after molecular design, creating iterative cycles that can slow candidate selection and consume valuable resources.

This white paper explores a deep learning framework that integrates multi-endpoint ADMET compliance directly into the molecular generation process, helping guide lead optimization toward compounds with improved developability.

๐Š๐ž๐ฒ ๐€๐ซ๐ž๐š๐ฌ ๐ญ๐จ ๐‚๐จ๐ง๐ฌ๐ข๐๐ž๐ซ:
โ€ข Embedding ADMET considerations directly into molecular generation
โ€ข Combining sequence-based and graph-based neural networks
โ€ข Using task-specific ADMET models to guide compound selection
โ€ข Applying reinforcement learning to optimize molecular candidates
โ€ข Advancing high-scoring compounds to confirmatory laboratory assays
โ€ข Improving the predictability and efficiency of lead optimization

๐–๐ก๐ฒ ๐ˆ๐ญ ๐Œ๐š๐ญ๐ญ๐ž๐ซ๐ฌ ๐Ÿ๐จ๐ซ ๐ƒ๐ซ๐ฎ๐  ๐ƒ๐ž๐ฏ๐ž๐ฅ๐จ๐ฉ๐ฆ๐ž๐ง๐ญ:
Integrating ADMET considerations earlier in lead optimization can help researchers identify liabilities sooner, reduce unnecessary development cycles, and prioritize candidates with a stronger balance of efficacy and developability.

By combining generative AI, predictive ADMET modeling, and reinforcement learning, drug discovery teams can move toward a more data-driven and efficient approach to candidate optimization.

๐‘๐ž๐š๐ ๐ญ๐ก๐ž ๐–๐ก๐ข๐ญ๐ž ๐๐š๐ฉ๐ž๐ซ:
https://www.pharmafocusasia.com/whitepapers/neural-network-driven-lead-optimization

Address

111, 112 First Floor, Block 2, White House
Hyderabad
500016

Website

Alerts

Be the first to know and let us send you an email when Pharma Focus Asia posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Pharma Focus Asia:

Shortcuts

Share